Vaccine design : the subunit and adjuvant approach /
Saved in:
| Imprint: | New York : Plenum Press, c1995. |
|---|---|
| Description: | xliv, 949 p. : ill. ; 24 cm. |
| Language: | English |
| Series: | Pharmaceutical biotechnology v. 6 The language of science Language of science. |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/2365961 |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | 2365961 | ||
| 003 | ICU | ||
| 005 | 20030520192100.0 | ||
| 008 | 950616s1995 nyua b 001 0 eng u | ||
| 010 | |a 95016401 | ||
| 020 | |a 030644867X | ||
| 035 | |a (ICU)BID20254988 | ||
| 040 | |a DLC |c DLC |d DLC |d OrLoB-B |d OCoLC | ||
| 041 | 0 | |a eng | |
| 050 | 0 | 0 | |a QR189 |b .V24 1995 |
| 082 | 0 | 0 | |a 615/.372 |2 20 |
| 245 | 0 | 0 | |a Vaccine design : |b the subunit and adjuvant approach / |c edited by Michael F. Powell and Mark J. Newman ; assistant editor, Jessica R. Burdman ; with a foreword by Jonas Salk. |
| 260 | |a New York : |b Plenum Press, |c c1995. | ||
| 300 | |a xliv, 949 p. : |b ill. ; |c 24 cm. | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a unmediated |b n |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/n | ||
| 338 | |a volume |b nc |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/nc | ||
| 440 | 0 | |a Pharmaceutical biotechnology |v v. 6 | |
| 490 | 1 | |a The language of science | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |g Ch. 1. |t Immunological and Formulation Design Considerations for Subunit Vaccines / |r Mark J. Newman and Michael F. Powell -- |g Ch. 2. |t Public Health Implications of Emerging Vaccine Technologies / |r Dale N. Lawrence, Karen L. Goldenthal, John W. Boslego, Donna K. F. Chandler and John R. La Montagne -- |g Ch. 3. |t Preclinical Safety Assessment Considerations in Vaccine Development / |r Jeanine L. Bussiere, George C. McCormick and James D. Green -- |g Ch. 4. |t Regulatory Considerations in Vaccine Design / |r Lawrence W. Davenport -- |g Ch. 5. |t Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines / |r Patricia E. Fast, Leigh A. Sawyer and Susan L. Wescott -- |g Ch. 6. |t Laboratory Empiricism, Clinical Design, and Social Value: The Rough Road toward Vaccine Development / |r Donald P. Francis -- |g Ch. 7. |t A Compendium of Vaccine Adjuvants and Excipients / |r Frederick R. Vogel and Michael F. Powell -- |g Ch. 8. |t Adjuvant Properties of Aluminum and Calcium Compounds / |r Rajesh K. Gupta, Bradford E. Rost, Edgar Relyveld and George R. Siber -- |g Ch. 9. |t Structure and Properties of Aluminum-Containing Adjuvants / |r Stanley L. Hem and Joe L. White -- |g Ch. 10. |t MF59: Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines / |r Gary Ott, Gail L. Barchfeld, David Chernoff, Ramachandran Radhakrishnan, Peter van Hoogevest and Gary Van Nest -- |g Ch. 11. |t Development of Vaccines Based on Formulations Containing Nonionic Block Copolymers / |r Robert N. Brey -- |g Ch. 12. |t Development of an Emulsion-Based Muramyl Dipeptide Adjuvant Formulation for Vaccines / |r Deborah M. Lidgate and Noelene E. Byars -- |g Ch. 13. |t Liposomal Presentation of Antigens for Human Vaccines / |r Reinhard Gluck -- |g Ch. 14. |t Liposome Design and Vaccine Development / |r Patricia J. Freda Pietrobon -- |g Ch. 15. |t Lipid Matrix-Based Vaccines for Mucosal and Systemic Immunization / |r Raphael J. Mannino and Susan Gould-Fogerite -- |g Ch. 16. |t Polymer Microspheres for Vaccine Delivery / |r Justin Hanes, Masatoshi Chiba and Robert Langer -- |g Ch. 17. |t Vehicles for Oral Immunization / |r Noemi Santiago, Susan Haas and Robert A. Baughman -- |g Ch. 18. |t Design and Production of Single-Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems / |r Jeffrey L. Cleland -- |g Ch. 19. |t Nanoparticles as Adjuvants for Vaccines / |r Jorg Kreuter -- |g Ch. 20. |t Water-Soluble Phosphazene Polymers for Parenteral and Mucosal Vaccine Delivery / |r Lendon G. Payne, Sharon A. Jenkins, Alexander Andrianov and Bryan E. Roberts -- |g Ch. 21. |t Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions / |r J. Terry Ulrich and Kent R. Myers -- |g Ch. 22. |t Structural and Immunological Characterization of the Vaccine Adjuvant QS-21 / |r Charlotte Read Kensil, Jia-Yan Wu and Sean Soltysik -- |g Ch. 23. |t A Novel Generation of Viral Vaccines Based on the ISCOM Matrix / |r G. F. Rimmelzwaan and A. D. M. E. Osterhaus -- |g Ch. 24. |t Vaccine Adjuvants Based on Gamma Inulin / |r Peter D. Cooper -- |g Ch. 25. |t A New Approach to Vaccine Adjuvants: Immunopotentiation by Intracellular T-Helper-Like Signals Transmitted by Loxoribine / |r Michael G. Goodman -- |g Ch. 26. |t Stearyl Tyrosine: An Organic Equivalent of Aluminum-Based Immunoadjuvants / |r Christopher Penney -- |g Ch. 27. |t Cytokines as Vaccine Adjuvants: Current Status and Potential Applications / |r Penny Dong, Carsten Brunn and Rodney J. Y. Ho -- |g Ch. 28. |t Cytokines as Immunological Adjuvants / |r Andrew W. Heath -- |g Ch. 29. |t Cytokine-Containing Liposomes as Adjuvants for Subunit Vaccines / |r Lawrence B. Lachman, Li-Chen N. Shih, Xiao-Mei Rao, Stephen E. Ullrich and Jeffrey L. Cleland -- |g Ch. 30. |t Haemophilus influenzae Type b Conjugate Vaccines / |r Peter J. Kniskern, Stephen Marburg and Ronald W. Ellis -- |g Ch. 31. |t Pneumococcal Conjugate Vaccines / |r Ronald Eby -- |g Ch. 32. |t Lyme Vaccine Enhancement: N-Terminal Acylation of a Protein Antigen and Inclusion of a Saponin Adjuvant / |r Richard T. Coughlin, Jianneng Ma and Daniel E. Cox -- |g Ch. 33. |t Vaccine Research and Development for the Prevention of Filarial Nematode Infections / |r Robert B. Grieve, Nancy Wisnewski, Glenn R. Frank and Cynthia A. Tripp -- |g Ch. 34. |t Retrovirus and Retrotransposon Particles as Antigen Presentation and Delivery Systems / |r Sally E. Adams and Alan J. Kingsman -- |g Ch. 35. |t Rationale and Approaches to Constructing Preerythrocytic Malaria Vaccines / |r Stephen L. Hoffman and John B. Sacci, Jr. -- |g Ch. 36. |t The MAP System: A Flexible and Unambiguous Vaccine Design of Branched Peptides / |r Bernardetta Nardelli and James P. Tam -- |g Ch. 37. |t Design of Experimental Synthetic Peptide Immunogens for Prevention of HIV-1 and HTLV-I Retroviral Infections / |r Mary Kate Hart, Thomas J. Palker and Barton F. Haynes -- |g Ch. 38. |t Design and Testing of Peptide-Based Cytotoxic T-Cell-Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer / |r Robert W. Chesnut, Alessandro Sette, Esteban Celis, Peggy Wentworth, Ralph T. Kubo, Jeff Alexander, Glenn Ishioka, Antonella Vitiello and Howard M. Grey -- |g Ch. 39. |t Development of Active Specific Immunotherapeutic Agents Based on Cancer-Associated Mucins / |r John Samuel and B. Michael Longenecker -- |g Ch. 40. |t Synthetic Peptide Vaccines for Schistosomiasis / |r Donald A. Harn, Sandra R. Reynolds, Silas Chikunguwo, Steve Furlong and Charles Dahl -- |g Ch. 41. |t Synthetic Hormone/Growth Factor Subunit Vaccine with Application to Antifertility and Cancer / |r Laura L. Snyder, David V. Woo, Pierre L. Triozzi and Vernon C. Stevens. |
| 650 | 0 | |a Vaccines. |0 http://id.loc.gov/authorities/subjects/sh85141718 | |
| 650 | 0 | |a Immunological adjuvants. |0 http://id.loc.gov/authorities/subjects/sh85000895 | |
| 650 | 7 | |a Immunological adjuvants. |2 fast |0 http://id.worldcat.org/fast/fst00967992 | |
| 650 | 7 | |a Vaccines. |2 fast |0 http://id.worldcat.org/fast/fst01163573 | |
| 700 | 1 | |a Powell, Michael F. |0 http://id.loc.gov/authorities/names/n95037340 |1 http://viaf.org/viaf/60790683 | |
| 700 | 1 | |a Newman, Mark J. |0 http://id.loc.gov/authorities/names/n95037341 |1 http://viaf.org/viaf/270869717 | |
| 700 | 1 | |a Burdman, Jessica R. |0 http://id.loc.gov/authorities/names/n95095897 |1 http://viaf.org/viaf/28783854 | |
| 830 | 0 | |a Language of science. |0 http://id.loc.gov/authorities/names/n86710083 | |
| 901 | |a ToCBNA | ||
| 903 | |a HeVa | ||
| 903 | |a Hathi | ||
| 035 | |a (OCoLC)32430019 | ||
| 929 | |a cat | ||
| 999 | f | f | |i 930a5905-0c22-5e50-8bfa-20b28776b53c |s 9586e331-8e17-5502-b63d-294dd2e832a7 |
| 928 | |t Library of Congress classification |a QR189.V240 1995 |l JCL |c JCL-Sci |i 3422285 | ||
| 927 | |t Library of Congress classification |a QR189.V240 1995 |l JCL |c JCL-Sci |e CRERAR |b 42921159 |i 4238281 | ||
